tradingkey.logo

Genfit SA

GNFT
4.065USD
-0.045-1.09%
Close 11/11, 16:00ETQuotes delayed by 15 min
203.26MMarket Cap
--P/E TTM

Genfit SA

4.065
-0.045-1.09%

More Details of Genfit SA Company

Genfit SA is a France-based biopharmaceutical company focused on the discovery and development of therapeutic and diagnostic solutions in the field of liver diseases, particularly of metabolic origin, where unmet medical needs are considerable, particularly due to a lack of approved treatments. The Company provides therapeutic and diagnostic solutions for rare and serious liver diseases , with a particular interest in diseases with largely unmet medical needs. Its laboratory capabilities include pharmacology, molecular and cellular biology, drug candidate screening, medicinal and analytical chemistry, biochemistry, omics analyses, and data science. Its in-house biobank allows to have unparalleled control and precision in the handling and preservation of biological samples, which is crucial to research. The Company leverage artificial intelligence (image processing tools and language models) to create tools that accelerate daily work and decision-making.

Genfit SA Info

Ticker SymbolGNFT
Company nameGenfit SA
IPO dateDec 19, 2006
CEOMr. Pascal Prigent
Number of employees180
Security typeOrdinary Share
Fiscal year-endDec 19
AddressParc Eurasante 885 avenue Eugene Avinee
CityLOOS
Stock exchangeEuronext Paris
CountryFrance
Postal code59120
Phone33320164000
Websitehttps://www.genfit.fr/
Ticker SymbolGNFT
IPO dateDec 19, 2006
CEOMr. Pascal Prigent

Company Executives of Genfit SA

Name
Name/Position
Position
Shareholding
Change
Mr. Tom Huijbers
Mr. Tom Huijbers
Executive Vice President - Regulatory
Executive Vice President - Regulatory
--
--
Ms. Sandra Silvestri, M.D., Ph.D.
Ms. Sandra Silvestri, M.D., Ph.D.
Director, Representative of IPSEN
Director, Representative of IPSEN
--
--
Dr. Carol Addy, M.D.
Dr. Carol Addy, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
--
--
Mr. Pascal Caisey
Mr. Pascal Caisey
Chief Operating Officer
Chief Operating Officer
--
--
Mr. Pascal Prigent
Mr. Pascal Prigent
Chief Executive Officer
Chief Executive Officer
--
--
Mr. John Brozek
Mr. John Brozek
Executive Vice President - Data and Information Technology
Executive Vice President - Data and Information Technology
--
--
Mr. Jean-Christophe Marcoux
Mr. Jean-Christophe Marcoux
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
Chief Corporate Affairs Officer, Head of Investor Relations, Head of ESG
--
--
Dr. Catherine Larue, Ph.D.
Dr. Catherine Larue, Ph.D.
Independent Director
Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Tom Huijbers
Mr. Tom Huijbers
Executive Vice President - Regulatory
Executive Vice President - Regulatory
--
--
Ms. Sandra Silvestri, M.D., Ph.D.
Ms. Sandra Silvestri, M.D., Ph.D.
Director, Representative of IPSEN
Director, Representative of IPSEN
--
--
Dr. Carol Addy, M.D.
Dr. Carol Addy, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Florence Sejourne
Ms. Florence Sejourne
Director, Representative of Biotech Avenir SAS
Director, Representative of Biotech Avenir SAS
--
--
Ms. Katherine Bach Kalin
Ms. Katherine Bach Kalin
Independent Director
Independent Director
--
--
Mr. Pascal Caisey
Mr. Pascal Caisey
Chief Operating Officer
Chief Operating Officer
--
--

Revenue Breakdown

No Data
No Data
By Business
By Region
No Data

Shareholding Stats

Updated: Sat, Aug 16
Updated: Sat, Aug 16
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Morgan Stanley & Co. International Plc
0.05%
AllianceBernstein L.P.
0.04%
Citadel Advisors LLC
0.04%
Other
99.86%
Shareholders
Shareholders
Proportion
Morgan Stanley & Co. International Plc
0.05%
AllianceBernstein L.P.
0.04%
Citadel Advisors LLC
0.04%
Other
99.86%
Shareholder Types
Shareholders
Proportion
Research Firm
0.05%
Investment Advisor/Hedge Fund
0.05%
Hedge Fund
0.04%
Other
99.86%

Institutional Shareholding

Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
20
80.73K
0.16%
-686.95K
2025Q2
22
234.11K
0.47%
-547.30K
2025Q1
25
259.00K
0.52%
-1.29M
2024Q4
26
260.49K
0.52%
-1.21M
2024Q3
28
127.35K
0.26%
-1.36M
2024Q2
31
97.15K
0.20%
-1.36M
2024Q1
31
97.93K
0.20%
-1.42M
2023Q4
31
648.17K
1.30%
-1.34M
2023Q3
32
1.16M
2.33%
-1.43M
2023Q2
30
1.77M
3.54%
-496.41K
View more

Shareholder Activity

Name
Shares Held
Proportion
Change
Chg %
Date
Morgan Stanley & Co. International Plc
27.42K
0.05%
+1.90K
+7.45%
Jun 30, 2025
AllianceBernstein L.P.
22.36K
0.04%
+13.38K
+148.94%
Jun 30, 2024
Citadel Advisors LLC
18.76K
0.04%
+6.43K
+52.16%
Jun 30, 2025
UBS Financial Services, Inc.
4.08K
0.01%
+963.00
+30.89%
Jun 30, 2025
Geode Capital Management, L.L.C.
3.21K
0.01%
--
--
Aug 31, 2025
Osaic Holdings, Inc.
225.00
0%
+225.00
--
Jun 30, 2025
Principal Securities Inc
24.00
0%
+24.00
--
Jun 30, 2025
Qube Research & Technologies Ltd
--
0%
-98.00
-100.00%
Sep 30, 2024
BofA Global Research (US)
1.00
0%
-16.00
-94.12%
Jun 30, 2025
Millennium Management LLC
--
0%
-131.48K
-100.00%
Jun 30, 2025
View more

Related ETFs

Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
ActivePassive International Equity ETF
0%
ActivePassive International Equity ETF
Proportion0%

Dividend

A total of 0.00 USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data

Stock Split

Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
KeyAI